che-kai tsao, md, considers the various i-o and tki combinations available for 1st line rcc
Published 5 years ago • 20 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:30
che-kai tsao, md, on deciding between i-o tkis combinations indicated for the treatment of rcc
-
2:28
che-kai tsao, md, regarding the evolving landscape of metastatic clear cell rcc
-
0:40
che-kai tsao, md, discusses the current application of biomarkers in renal cell carcinoma
-
0:55
che-kai tsao, md, elaborates on results from the titan study in mcrpc from asco '19
-
1:50
che-kai tsao, md, offers opinion on the results of the enzamet study in mhspc
-
3:54
agena technology
-
4:30
take a tour of usc's stem cell research center
-
5:08
cellectis allogeneic car-t cells
-
1:22
tian zhang, md, regarding strategies for treating rcc in the 2nd line setting
-
1:20
michael atkins, md, offers opinion on io-tki combinations in renal cell cancer
-
1:28
tian zhang, md, discusses the most anticipated trial results regarding biomarkers in rcc
-
1:45
tian zhang, md, on predictive biomarkers in selecting patient populations for i-o treatment in rcc
-
23:09
9. cell type identification in scrna-seq data
-
12:26
what is an allogeneic car t cell?
-
18:31
apcca2019_031_session 5a: the role of ts-1 in cholangiocarcinoma (tty)
-
1:09
dr. casie shenoy, hematology/oncology
-
1:17
tian zhang, md, on the evolving landscape of metastatic hormone-sensitive prostate cancer
-
46:59
tanzer m (2016): from cytokine signalling to cell death
-
12:55
simote totauhelotu foliaki 2019 research grant recipient
-
1:16
dr. richard chang - hematology and oncology
-
29:19
molecular analysis of ctcs